{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:04:26Z","timestamp":1790899466216,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3564,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1093\/annonc\/mdp373","type":"journal-article","created":{"date-parts":[[2009,10,9]],"date-time":"2009-10-09T01:10:50Z","timestamp":1255050650000},"page":"474-480","source":"Crossref","is-referenced-by-count":74,"title":["An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer"],"prefix":"10.1016","volume":"21","author":[{"given":"G.","family":"Capri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Cwiertka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Jerusalem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sch\u00fctte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rosenlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Selzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Zembryki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdp373_bb0010","unstructured":"American Cancer SocietyGlobal Cancer Facts and Figures 2007 [on-line]; http:\/\/www.cancer.org\/docroot\/STT\/content\/STT_1x_Global_Cancer_Facts_and_Figures_2007.asp (10 March, 2009, date last accessed)"},{"key":"10.1093\/annonc\/mdp373_bb0015","doi-asserted-by":"crossref","unstructured":"S Johnston M Pegram M Press. Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 TrialAbstract presented at 31st Annual San Antonio Breast Cancer Symposium; December 10\u201314, 2008; San Antonio, TX","DOI":"10.1158\/0008-5472.SABCS-46"},{"key":"10.1093\/annonc\/mdp373_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S146239940600010X","article-title":"ErbB receptors and their ligands in the breast","volume":"8","author":"Zahnow","year":"2006","journal-title":"Expert Rev Mol Med"},{"key":"10.1093\/annonc\/mdp373_bb0025","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1172\/JCI32278","article-title":"ErbB receptors: from oncogenes to targeted cancer therapies","volume":"117","author":"Zhang","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdp373_bb0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10911-006-9009-1","article-title":"The ErbB2 signaling network as a target for breast cancer therapy","volume":"11","author":"Badache","year":"2006","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"10.1093\/annonc\/mdp373_bb0035","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1093\/annonc\/mdp373_bb0040","first-page":"85","article-title":"The effects of the novel, reversible epidermal growth factor receptor\/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo","volume":"1","author":"Rusnak","year":"2001","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdp373_bb0045","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdp373_bb0050","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10549-007-9885-0","article-title":"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses","volume":"112","author":"Cameron","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp373_bb0055","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","article-title":"Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer","volume":"26","author":"Di Leo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp373_bb0060","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1200\/JCO.2007.14.0590","article-title":"Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer","volume":"26","author":"Gomez","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp373_bb0065","doi-asserted-by":"crossref","unstructured":"F Boccardo B Kaufman J Baselga. Evaluation of lapatinib plus capecitabine in patients with brain metastases from HER2+ breast cancer enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU)Poster presented at 44th Annual Meeting of the American Society of Clinical Oncology; May 30\u2013June 3, 2008; Chicago, IL","DOI":"10.1200\/jco.2008.26.15_suppl.1094"},{"key":"10.1093\/annonc\/mdp373_bb0070","doi-asserted-by":"crossref","unstructured":"M Campone C El-Kouri P Cottu. French Lapatinib Authorization for Temporary Use (ATU): design, operation and initial safety dataPoster presented at 6th European Breast Cancer Conference; April 15\u201319, 2008; Berlin, Germany","DOI":"10.1016\/S1359-6349(08)70721-3"},{"key":"10.1093\/annonc\/mdp373_bb0075","unstructured":"S De Placido G Capri J Ro. Lapatinib Expanded Access Program (LEAP): updated safety dataPoster presented at European Society for Medical Oncology 33rd Annual Meeting; September 12\u201316, 2008; Stockholm, Sweden"},{"key":"10.1093\/annonc\/mdp373_bb0080","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/annonc\/mdn050","article-title":"Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias","volume":"19","author":"Capdeville","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp373_bb0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000111094","article-title":"An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer","volume":"72","author":"Venturini","year":"2007","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdp373_bb0090","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp373_bb0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.breast.2003.09.002","article-title":"Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer","volume":"13","author":"Suter","year":"2004","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdp373_bb0100","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdp373_bb0105","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","article-title":"Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials","volume":"83","author":"Perez","year":"2008","journal-title":"Mayo Clin Proc"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419383152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419383152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/3\/474\/398174\/mdp373.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:14:47Z","timestamp":1624518887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419383152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0923753419383152"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdp373","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}